Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus CERADON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus CERADON.
ASMANEX HFA vs CERADON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Unknown; possibly enhances cognitive function by modulating cholinergic and dopaminergic pathways.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
500 mg orally every 8 hours; for severe infections, 750 mg every 12 hours or 1 g every 8 hours.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
3-5 hours in healthy adults; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20 hours in severe impairment (CrCl <30 mL/min).
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total: >90% eliminated within 48 hours.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid